- Home
- / Avalon Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Avalon Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
﷼394 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| SAR | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|
| Revenue | 301.7M | 287.2M | 302.7M | 338.4M | 394.0M |
| Cost of goods sold | 121.0M | 108.4M | 114.4M | 126.9M | 139.6M |
| Gross profit | 180.6M | 178.9M | 188.3M | 213.1M | 255.5M |
| Gross profit margin, % | 59.9% | 62.3% | 62.2% | 63.0% | 64.8% |
| Operating expense total | 89.0M | 93.4M | 107.4M | 122.6M | 145.1M |
| Depreciation and amortization | 8.9M | 9.6M | 10.6M | 11.9M | 15.8M |
| EBITDA | 91.6M | 85.5M | 80.9M | 90.5M | 110.3M |
| EBITDA margin, % | 30.4% | 29.8% | 26.7% | 26.7% | 28.0% |
| EBIT | 82.8M | 76.0M | 70.4M | 78.7M | 94.6M |
| EBIT margin, % | 27.4% | 26.5% | 23.2% | 23.3% | 24.0% |
| Interest expense | 3.0M | 2.8M | 748.0K | 1.1M | 1.0M |
| Pre tax profit | 77.8M | 70.5M | 65.0M | 71.4M | 86.3M |
| Income tax expense | 5.0M | 4.2M | 5.6M | 5.6M | 6.5M |
| Net Income | 72.8M | 66.3M | 59.5M | 65.8M | 79.8M |